Drug
Stannsoporfin
Stannsoporfin is a pharmaceutical drug with 5 clinical trials. Historical success rate of 80.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_2
2
40%
Ph phase_3
1
20%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (66.7%)
Phase 31 (33.3%)
Trials by Status
terminated120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
completed
Follow up Study of Patients Having Participated in Clinical Trial 64,185-204
NCT02000830
completedphase_2
Stannsoporfin With Light Therapy for Newborn Babies With Jaundice
NCT01887327
terminatedphase_2
A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
NCT00850993
completedphase_3
Efficacy and Safety of Stannsoporfin in Neonates
NCT02685137
completed
Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)
NCT02033096
Clinical Trials (5)
Showing 5 of 5 trials
NCT02000830
Follow up Study of Patients Having Participated in Clinical Trial 64,185-204
NCT01887327Phase 2
Stannsoporfin With Light Therapy for Newborn Babies With Jaundice
NCT00850993Phase 2
A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
NCT02685137Phase 3
Efficacy and Safety of Stannsoporfin in Neonates
NCT02033096
Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5